louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00596921: Bedside Ultrasound Measurement of the Inferior Vena Cava Correlates to Central Venous Pressure
Official title: Bedside Ultrasound Measurement of the Inferior Vena Cava Correlates to Central Venous Pressure
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Shock
Hypovolemia
Hypervolemia
Keywords: Ultrasonography
Central Venous Pressure
Noninvasive monitoring
Shock
Resuscitation
Lead sponsor: Brooke Army Medical Center
Sponsor class: FED
First posted: 2008-01-17
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hospitalized patients with central venous monitoring in place.

Brief summary: This study proposes to examine the correlation of central venous pressure to measures of the diameter of the inferior vena cava as determined by bedside ultrasonography.

Detailed description: Central venous pressure (CVP) is a key physiologic estimate of preload, which in turn helps define the vascular fluid status. It is a particularly important parameter to measure in critically ill and injured patients who may require resuscitation. Unfortunately, measurement of the CVP requires invasive central venous catheters which can be difficult or time-consuming to insert. A non-invasive means of inferring the CVP would provide clinicians with an alternative. Preliminary data suggests that the diameter of the vena cava may reflect the CVP. Ultrasonography can provide reliable measures of internal body structures including the vena cava, and therefore may be useful in this regard. Collecting simultaneous values of vena cava diameter and CVPs will allow for the identification and quantification of correlation.

Eligibility criteria: Inclusion Criteria:

* CVP or right heart catheter that is already in place and functioning properly

Exclusion Criteria:

* Supine position or placement of ultrasound probe on abdomen is contraindicated.

Primary outcomes:
measure: Bedside ultrasound measurement of the diameter of the inferior vena cava and simultaneously measured central venous pressure.
timeFrame: Cross-sectional
Secondary outcomes:
measure: Anatomic view and phase of respiration at the time of measurements.
timeFrame: Cross-sectional
Other outcomes:
Locations:
Study officials:
affiliation: Brooke Army Medical Center
name: Robert A De Lorenzo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03074721: PCI Suite: Road Map Fusion Imaging in Coronary Diagnostics and Therapy
Official title: PCI Suite: Road Map Fusion Imaging in Coronary Diagnostics and Therapy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Coronary Disease
Lead sponsor: Heinrich-Heine University, Duesseldorf
Sponsor class: OTHER
Collaborators: name: Philips Medical Systems
First posted: 2017-03-09
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The PCI Suite is developed by Philips Medical Systems, a Philips Healthcare company. The proposed PCI Suite is a new software package which can be used during coronary interventions. The software package includes two sub-packages, known as StentBoost and Cardiac Roadmapping.

The patient will undergo standard of care medical treatment for his or her cardiac condition. During the procedure, the physician may make angiograms for diagnosis and as reference for device navigation as part of the standard care. These angiograms will be automatically processed in PCI Suite and displayed on fluoroscopy for navigation support. In case a balloon catheter is inserted into the coronary arteries, the physician may take cine images as part of the standard care. These images can be automatically enhanced in PCI Suite. The primary objective of this prospective, mono-center, randomized clinical trial is to evaluate the amount of contrast medium used during percutaneous coronary intervention.


Eligibility criteria: Inclusion Criteria:

* hemodynamically relevant type A or B lesion

Exclusion Criteria:

* hemodynamically relevant type C lesion
* NSTEMI/STEMI
* declined to participate

Primary outcomes:
measure: Amount of contrast medium
timeFrame: Baseline
Secondary outcomes:
measure: Major adverse cardiac and cerebrovascular events
timeFrame: Baseline, after 6 months, after 12 months
measure: Procedural success
timeFrame: Baseline
measure: Procedure duration
timeFrame: Baseline
measure: area dosage product
timeFrame: Baseline
Other outcomes:
Locations:
city: Dusseldorf
country: Germany
facility: Division of Cardiology, Pulmonary Disease and Vascular Medicine
Study officials:
affiliation: Division of Cardiology, Pulmonology and Vascular Medicine, University Hospital Duesseldorf
name: Tobias Zeus, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04923321: Taste Supra-thresholds Among a Sample of Depressed Egyptian Adult Under Anti-depressants Therapy
Official title: Taste Supra-thresholds Among a Sample of Depressed Egyptian Adults Under Anti-depressants Therapy A Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Taste Disorders
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2021-06-11
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Depressed Egyptian adults under anti-depressants therapy The patients will be recalled using their phone numbers recorded in their follow up records in order to come to the Diagnosis center at the faculty of Dentistry, Cairo University to be assessed for taste intensity at supra-threshold level and will be given identification numbers and divided into three groups, to which the operator shall be blinded.

Brief summary: Determine the taste intensity at supra-threshold among a sample of depressed Egyptian adults (age from 20 to 50 years old) under anti-depressants therapy ( for at least 3 months) using filter paper disc(FPD) method using a psychophysical method through a scoring system.

Detailed description: PECO

* P Population: depressed Egyptian adults under anti-depressants therapy
* E1 Exposure 1: Tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL)
* E2 Exposure 2: Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine)
* C control (non exposure) : non-pharmacological treatment ( psychotherapy)
* O Outcome: Determine the taste intensity at supra-threshold among these patients using a psychophysical method through a scoring system

Eligibility criteria: Inclusion Criteria:

* Depressed Egyptian adults under antidepressants therapy for at least 3 months/non-pharmacological treatment( psychotherapy) • Age from 20 to 50 years old

Exclusion Criteria:

* Antipsychotics

  * Hypnotics
  * Anticonvulsants
  * Ages other than the mentioned • Olfactory dysfunction
  * Chemosensory dysfunction

Primary outcomes:
measure: Taste intensity at supra-threshold
timeFrame: during a period of 3 months from February 2021 till April 2021]
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Dentistry, Cairo University
Study officials:
References:
Clinical trial NCT04664621: HepQuant to Predict Hepatic Encephalopathy After TIPS
Official title: HepQuant to Predict Hepatic Encephalopathy in Patients Who Receive Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Refractory Ascites - a Pilot Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Hepatic Encephalopathy
Cirrhosis, Liver
Lead sponsor: Northwestern University
Sponsor class: OTHER
Collaborators: name: HepQuant, LLC
First posted: 2020-12-11
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: A pilot study to determine if a simple blood test can predict patients at risk for significant episodes of confusion and disorientation that can occur in patients who receive an artificial shunt through the liver to control complications of liver disease.


Eligibility criteria: Inclusion Criteria:

* Subjects over the age of 18 able to provide consent
* Subjects undergoing initial TIPS procedure for the primary indication of treatment of ascites

Exclusion Criteria:

* Prisoners
* Pregnant women
* Subjects undergoing TIPS placement as part of an investigational study outside of usual clinical care
* Subjects taking beta-blocker medications or angiotensin converting enzyme inhibitors
* Subjects with evidence of porto-systemic shunts present on imaging (eg splenorenal shunt)
* Subjects with calculated MELD score \>12 based on most recent laboratory values before consent
* Subjects with prior history of overt hepatic encephalopathy (grade 3-4) that was primary reason for hospitalization. Episodes of hepatic encephalopathy that were the consequence of other precipitating event (such as variceal bleeding or infection) will not be considered exclusionary.
* Subjects with a known sensitivity to albumin preparations, any ingredient in the formulation, or components of the container
* Subjects unable to fast for \>5 hours prior to the HepQuant administration or subjects who are unable to drink the oral dose of the cholate (\~40mL of liquid).

Primary outcomes:
measure: Onset of Hepatic Encephalopathy
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Northwestern University
state: Illinois
Study officials:
References:
Clinical trial NCT05395221: Making Resident Well-Being a (Virtual) Reality
Official title: Making Resident Well-Being a (Virtual) Reality
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Mental Health
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2022-05-27
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study is a prospective cross-over trial examining the effect of virtual reality assisted meditation on resident reported well-being using validated scoring systems. The primary objective of this study is to evaluate the effectiveness of virtual reality guided meditation as a mechanism to improve plastic surgery resident well-being. The secondary objective is to assess resident likeliness to continue mindful meditation following completion of the study.

Detailed description: All plastic surgery residents participating will spend three months with access to virtual reality assisted meditation and three months without access to this technology. Assessment scores will be taken before and after the first three month period, and then again following the second three month period.

Eligibility criteria: Inclusion Criteria:

* Current resident of NYU Langone Plastic Surgery (Academic Year 2022-2023)
* Consent to participation in the study

Exclusion Criteria:

* Any plastic surgery resident involved in conducting the study
* Any non-plastic surgery resident during the academic year 2022-2023
* Any plastic surgery resident choosing not to participate in the study

Primary outcomes:
measure: Change in Emotional Exhaustion as measured by Maslach Burnout Inventory (MBI)
timeFrame: Baseline, 3 month visit, 6 month visit
measure: Change in Depersonalization as measured by Maslach Burnout Inventory (MBI)
timeFrame: Baseline, 3 month visit, 6 month visit
measure: Change in personal accomplishment as measured by Maslach Burnout Inventory (MBI)
timeFrame: Baseline, 3 month visit, 6 month visit
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: NYU Langone Health
name: Vishal Thanik
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03493321: Role of PRF With MTA and Theracal After Pulpotomy in Relieving Pain
Official title: Role of PRF With MTA and Theracal After Pulpotomy in Relieving Pain and Maintaining the Vitality of the Remaining Radicular Pulp Tissue in Permanent Posterior Teeth With Closed Root Apices: "Randomized Controlled Trial"
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Neuritis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-04-10
Enrollment: 98
Sex: ALL
Minimum age (years): 16
Maximum age (years): 35
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: this research will evaluate the effect of PRF with different bioactive materials in dentistry

Detailed description: PRF will be used with MTA and Theracal to evaluate its effect upon these materials in reliving pain and maintains the teeth vitality in permanent teeth with closed apices, in order to improve the materials outcome.

Eligibility criteria: Inclusion Criteria:

* Patients suffering from Symptomatic pulpitis.
* Patients should be free from any systemic disease that may affect normal healing and predictable outcome.
* Patients who will agree to the consent and will commit to follow-up period.
* Patients with mature root.
* Patients with no periapical lesion.
* Patients with localized pain.
* Posterior teeth only will be involved

Exclusion Criteria:

* Patients with immature roots.
* Patients with any systemic disease that may affect normal healing.
* Patients with periapical lesions or infections.
* Pregnant females.
* Patients who could/would not participate in a 1-year follow-up.
* Patients with fistula.
* Patients with necrotic pulp.
* Patients with old age.

Primary outcomes:
measure: pain after the process
timeFrame: 1 year
Secondary outcomes:
measure: dentin bridge formation
timeFrame: 1 year
measure: no periapical radiolucency
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00798421: Study to Evaluate Nosocomial Transmission of Influenza
Official title: Pilot Study to Develop a Model to Evaluate Nosocomial Transmission of Influenza
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Influenza
Keywords: Influenza, transmission
Lead sponsor: University Hospitals, Leicester
Sponsor class: OTHER
First posted: 2008-11-26
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1. Healthy subject volunteers \> 18 years of age
2. Children with confirmed influenza presenting to the Children's Hospital, Leicester Royal Infirmary

Brief summary: The purpose of this study is to investigate whether influenza can be reliably transmitted from children to susceptible contacts in a health care setting. The goal is to develop a transmission that can then be used to assess interventions to prevent transmission

Research objectives:

To develop a model to investigate the frequency of influenza transmission from an infected child to a susceptible health care worker

Research Hypotheses:

Influenza viruses can be transmitted from infected children to exposed health care workers

Detailed description: CHildren with influenza infection presenting to ED will be identified by RAT. Healthy healthcare worker subjects will expose themselves and perform specific activities with the child.

subjects will be followed by diary card, clinical symptom scores and virology swabs to assess frequency of transmission

Eligibility criteria: Inclusion criteria:

* Infected Children

  * Age \< 16 years
  * Parents or legal guardians willing to give informed written consent
  * Presenting with a febrile illness confirmed as influenza by near patient rapid antigen testing
* Healthy volunteers

  * Willing to give informed written consent

Exclusion criteria

* Children

  * No parents or legal guardians able to give informed consent
* Healthy volunteers

  * known allergy to oseltamivir or zanamivir
  * presence of underlying condition or concomitant therapy requiring dose alteration of oseltamivir (severe renal or hepatic failure; methotrexate and probenecid)
  * underlying immunosuppressive disorder
  * known galactose intolerance
  * underlying chronic medical condition known to increase risk of influenza-related complications (including asthma, chronic pulmonary airways disease, chronic cardiovascular disease, diabetes mellitus, chronic neurological disorder)
  * inability or contraindication to collection of nasal swabs
  * previous influenza vaccination within 2 years
  * current smoker
  * pregnancy

Primary outcomes:
measure: Frequency of transmission of influenza
timeFrame: 1 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Leicester
country: United Kingdom
facility: University Hospitals Leicester
state: Leics
Study officials:
affiliation: University Hospitals, Leicester
name: Iain Stephenson, FRCP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02169921: TurboHawk™ Japan Trial in Patients With PAD
Official title: Determination of Safety and Effectiveness of the TurboHawk and the SpiderFX for the Treatment of Peripheral Arterial Disease in the Superficial Femoral and/or the Popliteal Arteries in Japan
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Peripheral Arterial Disease
Lead sponsor: Medtronic Endovascular
Sponsor class: INDUSTRY
First posted: 2014-06-23
Enrollment: 51
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of this study is to evaluate the safety and effectiveness of the TurboHawk for the treatment of peripheral arterial disease (PAD) in the superficial femoral and/or the popliteal arteries with the Japanese population.


Eligibility criteria: Inclusion Criteria:

* Provides written informed consent
* Willing to comply with follow-up evaluations at specified times
* Has a Rutherford Clinical Category Score of 2-4
* Disease located within the femoropopliteal artery
* Has evidence of ≥ 50% stenosis or occlusion in the superficial femoral and/or popliteal, confirmed by angiography
* Each discrete target lesion's length is ≥4cm and ≤ 15 cm
* Reference vessel diameter is ≥ 3.5 mm and ≤ 7.0 mm

Exclusion Criteria:

* Previously implanted stent(s) or stent graft(s) in target leg
* Life expectancy less than 12 months
* Has any planned surgical or endovascular intervention of target vessel 30 days before or after index procedure
* Has in-stent restenosis of the target lesion
* Has an aneurysmal target vessel
* Has perforation, dissection or other injury of the access or target vessel requiring additional stenting or surgical intervention prior to enrollment

Primary outcomes:
measure: Primary Patency Rate
timeFrame: 180 Days
Secondary outcomes:
measure: Technical procedural success
timeFrame: 30 Days
measure: Preservation of the number of run-off vessels determined by angiography
timeFrame: intra operative
measure: Event free survival
timeFrame: 30 Days , 180 Days and One Year
measure: Amputation Rate
timeFrame: 30 Days , 180 Days and One Year
measure: Improvement in Rutherford Clinical Category
timeFrame: 30 Days , 180 Days and One Year
measure: Improvement in Ankle-Brachial Index
timeFrame: 30 Days , 180 Days and One Year
measure: Clinically driven target lesion revascularisation
timeFrame: 30 Days , 180 Days and One Year
measure: Clinically driven target vessel revascularisation
timeFrame: 30 Days , 180 Days and One Year
Other outcomes:
Locations:
city: Kasukabe
country: Japan
facility: Kasukabe Chuo General Hospital
state: Saitama
city: Minato-ku
country: Japan
facility: Jikei University School of Medicine
state: Tokyo
Study officials:
affiliation: Jikei University School of Medicine
name: Takao Ohki, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Kasukabe Chuo General Hospital
name: Hiroshi Ando, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05544721: A Study of Paravertebral Block in Thoracic Outlet Syndrome
Official title: Pre-Operative and Post-Operative Paravertebral Block on Patients With Thoracic Outlet Syndrome.
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: PHASE4
Conditions: Thoracic Outlet Syndrome
Keywords: First rib resection procedure
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2022-09-16
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This research is being done to evaluate the effects of receiving only a paravertebral block prior to first rib resection procedure versus receiving the block both pre and post procedure.


Eligibility criteria: Inclusion Criteria:

- All Thoracic Outlet Syndrome patients scheduled for first rib resection surgery.

Exclusion Criteria:

* Patients who are pregnant.
* Patients with prior first rib resection on side of presentation.
* Patients with complex regional pain syndrome (CRPS).
* Patients with brachial plexus disorder.
* Patients with cervical rib.

Primary outcomes:
measure: Change in pain level
timeFrame: Time of discharge (approximately 1 day), day 1 post-op, day 3 post-op, day 7 post-op, and day 14 post-op
Secondary outcomes:
measure: Change in quality of life
timeFrame: Time of discharge (approximately 1 day), day 1 post-op, day 3 post-op, day 7 post-op, and day 14 post-op
measure: Length of stay
timeFrame: Approximately 1 day
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic in Florida
state: Florida
Study officials:
affiliation: Mayo Clinic
name: Houssam Farres, MD
role: PRINCIPAL_INVESTIGATOR
References: